Stu Peltz, Ph.D., CEO and Founder of PTC Therapeutics, discusses the Talent Pipeline Program, a global internship program the company launched last year to help newly graduated students during the COVID-19 pandemic. Through the internship program, recent graduates received real-world work experience and training across all departments from research through commercialization. He provides a look over the past year, highlighting how successful the program has been and discussing how innovative internship programs can make a major difference for graduates.
Dr. Peltz founded PTC Therapeutics in 1998 and has served as Chief Executive Officer and a member of the board of directors since the company’s inception. Under his leadership, PTC has grown from a research organization to a publicly traded, global commercial organization with multiple approved products and a foundation of strong technology platforms that continues to drive a robust discovery pipeline for patients with rare disorders. Prior to founding PTC, Dr. Peltz was a Professor in the Department of Molecular Genetics & Microbiology at the Robert Wood Johnson Medical School, Rutgers University. Dr. Peltz is a recognized scientific leader in RNA biology in the area of post-transcriptional control processes involving mRNA turnover and translation, with more than 30 years of research and over 100 publications in this area. Dr. Peltz received a Ph.D. from the McArdle Laboratory for Cancer Research at the University of Wisconsin.